DiagnoSearch Life Sciences, one of India’s longest-standing and most trusted Clinical Research Organisations (CROs), has completed 30 years of delivering high-quality, compliant, and scientifically rigorous clinical research solutions. The milestone reflects the growing maturity of India’s CRO ecosystem and signals strengthened capabilities available to pharmaceutical, biotech, and medical device innovators worldwide.

Founded in 1995, DiagnoSearch has evolved from a central laboratory services provider into a full-service CRO with global reach, offering end-to-end support across clinical operations, central lab services, medical affairs and safety management, data management and biostatistics, and scientific and regulatory writing. The organisation has supported hundreds of clinical studies across multiple therapeutic areas, contributing significantly to accelerated drug development and regulatory approvals across India, APAC, Africa, and other emerging markets.

Leadership Vision: Scaling Globally, Innovating Boldly

Reflecting on the company’s 30-year journey,
Dr. Manisha Ginde, Co-Founder, President & Managing Director, DiagnoSearch Life Sciences, said:

“Completing 30 years is a meaningful milestone for us, shaped by scientific rigour, the trust of our sponsors, and the steadfast commitment of our teams. Every stage of our journey has strengthened our resolve to deliver high-quality research that contributes to safe, effective therapies for patients worldwide.”

Dr. Vinod Mattoo, Executive Director, DiagnoSearch Life Sciences, added:

“As we celebrate three decades of DiagnoSearch, we are excited to focus on global scalability, deeper therapeutic specialisation, and the adoption of advanced technologies. The future of DiagnoSearch is defined by innovation, ambition, and lasting impact in clinical research.”

Implications for the Pharma Industry

For pharmaceutical and biotech companies, DiagnoSearch’s milestone underscores the availability of a stable, seasoned, and globally capable CRO partner at a time when drug development demands speed, precision, and regulatory certainty.
Key benefits for industry sponsors include:

• Access to a 30-year partner with proven operational reliability
• High-quality datasets supporting multi-country regulatory submissions
• Faster study timelines through global patient reach across APAC & Africa
• Strong compliance frameworks aligned with global regulatory expectations
• Enhanced therapeutic depth and digital readiness for modern trial designs

Also read: Intas Pharma Strengthens Leadership with Appointment of Vijay Dabade as Associate Vice President – Quality Control

A 30-Year Legacy of Trust, Data Integrity & Operational Excellence

Over the last three decades, DiagnoSearch has built a reputation for rigorous data quality, ethical research practices, and meticulous regulatory adherence—core priorities for pharmaceutical companies navigating increasingly complex clinical development pipelines. Its scientific output has supported approvals for innovative therapies across diverse geographies, strengthening India’s role as a reliable global clinical research hub.

The anniversary celebration, held at the company’s Mumbai headquarters, brought together alumni, long-standing collaborators, and employees who have shaped the organisation’s growth and culture. The event also highlighted DiagnoSearch’s continued commitment to innovation, global expansion, and advanced technology adoption.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!